Literature DB >> 27174038

Learning from PD-1 Resistance: New Combination Strategies.

Xia Bu1, Kathleen M Mahoney2, Gordon J Freeman3.   

Abstract

Only a minority of cancer patients respond to anti PD-1 immunotherapy. A recent study demonstrates that PD-1 therapy-resistant melanoma patients present distinct signatures of upregulated genes involved in immunosuppression, angiogenesis, monocyte and macrophage chemotaxis, extracellular matrix remodeling, and epithelial-mesenchymal transition (EMT). Combination targeting of these pathways with PD-1 may help overcome PD-1 resistance, thus producing effective antitumor immunity.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2016        PMID： 27174038      PMCID： PMC6833952          DOI： 10.1016/j.molmed.2016.04.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  9 in total

1.  Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Authors:  Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

2.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Authors:  Willy Hugo; Hubing Shi; Lu Sun; Marco Piva; Chunying Song; Xiangju Kong; Gatien Moriceau; Aayoung Hong; Kimberly B Dahlman; Douglas B Johnson; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2015-09-10       Impact factor: 41.582

3.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

4.  RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Authors:  Sherene Loi; Sathana Dushyanthen; Paul A Beavis; Roberto Salgado; Carsten Denkert; Peter Savas; Susan Combs; David L Rimm; Jennifer M Giltnane; Monica V Estrada; Violeta Sánchez; Melinda E Sanders; Rebecca S Cook; Mark A Pilkinton; Simon A Mallal; Kai Wang; Vincent A Miller; Phil J Stephens; Roman Yelensky; Franco D Doimi; Henry Gómez; Sergey V Ryzhov; Phillip K Darcy; Carlos L Arteaga; Justin M Balko
Journal:  Clin Cancer Res       Date:  2015-10-29       Impact factor: 12.531

5.  Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.

Authors:  Nicolas A Giraldo; Etienne Becht; Franck Pagès; Georgios Skliris; Virginie Verkarre; Yann Vano; Arnaud Mejean; Nicolas Saint-Aubert; Laetitia Lacroix; Ivo Natario; Audrey Lupo; Marco Alifano; Diane Damotte; Aurelie Cazes; Frederic Triebel; Gordon J Freeman; Marie-Caroline Dieu-Nosjean; Stephane Oudard; Wolf H Fridman; Catherine Sautès-Fridman
Journal:  Clin Cancer Res       Date:  2015-02-16       Impact factor: 12.531

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

7.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

8.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Authors:  Peter J R Ebert; Jeanne Cheung; Yagai Yang; Erin McNamara; Rebecca Hong; Marina Moskalenko; Stephen E Gould; Heather Maecker; Bryan A Irving; Jeong M Kim; Marcia Belvin; Ira Mellman
Journal:  Immunity       Date:  2016-03-02       Impact factor: 31.745

9.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Authors:  Shohei Koyama; Esra A Akbay; Yvonne Y Li; Grit S Herter-Sprie; Kevin A Buczkowski; William G Richards; Leena Gandhi; Amanda J Redig; Scott J Rodig; Hajime Asahina; Robert E Jones; Meghana M Kulkarni; Mari Kuraguchi; Sangeetha Palakurthi; Peter E Fecci; Bruce E Johnson; Pasi A Janne; Jeffrey A Engelman; Sidharta P Gangadharan; Daniel B Costa; Gordon J Freeman; Raphael Bueno; F Stephen Hodi; Glenn Dranoff; Kwok-Kin Wong; Peter S Hammerman
Journal:  Nat Commun       Date:  2016-02-17       Impact factor: 14.919
  9 in total
  31 in total

Review 1.  Targeting IL-17 in psoriatic arthritis.

Authors:  Elizabeth A Wang; Erika Suzuki; Emanual Maverakis; Iannis E Adamopoulos
Journal:  Eur J Rheumatol       Date:  2017-11-10

2.  Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ.

Authors:  Chang Liu; Maria Chikina; Rahul Deshpande; Ashley V Menk; Ting Wang; Tracy Tabib; Erin A Brunazzi; Kate M Vignali; Ming Sun; Donna B Stolz; Robert A Lafyatis; Wei Chen; Greg M Delgoffe; Creg J Workman; Stacy G Wendell; Dario A A Vignali
Journal:  Immunity       Date:  2019-07-23       Impact factor: 31.745

3.  Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.

Authors:  Fang Zheng; Jianzhong Dang; Hongyu Zhang; Fangzhou Xu; Diandian Ba; Bingyu Zhang; Fanjun Cheng; Alfred E Chang; Max S Wicha; Qiao Li
Journal:  J Immunother       Date:  2018-10       Impact factor: 4.456

Review 4.  Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.

Authors:  Hazem E Ghoneim; Anthony E Zamora; Paul G Thomas; Ben A Youngblood
Journal:  Trends Mol Med       Date:  2016-11-04       Impact factor: 11.951

5.  Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.

Authors:  Yong Zhang; Yufen Zhao; Andrew J Tebben; Steven Sheriff; Max Ruzanov; Mark P Fereshteh; Yi Fan; Jonathan Lippy; Jesse Swanson; Ching-Ping Ho; Barri S Wautlet; Anne Rose; Karen Parrish; Zheng Yang; Andrew F Donnell; Liping Zhang; Brian E Fink; Gregory D Vite; Karen Augustine-Rauch; Joseph Fargnoli; Robert M Borzilleri
Journal:  ACS Med Chem Lett       Date:  2018-10-17       Impact factor: 4.345

Review 6.  Mechanisms of tumor immunotherapy, with a focus on thoracic cancers.

Authors:  Simona Ferro; Veronica Huber; Licia Rivoltini
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 7.  Functional genomics: paving the way for more successful cancer immunotherapy.

Authors:  Reham Ajina; Danielle Zamalin; Louis M Weiner
Journal:  Brief Funct Genomics       Date:  2019-03-22       Impact factor: 4.241

Review 8.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

9.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.

Authors:  Vasanthi S Viswanathan; Matthew J Ryan; Harshil D Dhruv; Shubhroz Gill; Ossia M Eichhoff; Brinton Seashore-Ludlow; Samuel D Kaffenberger; John K Eaton; Kenichi Shimada; Andrew J Aguirre; Srinivas R Viswanathan; Shrikanta Chattopadhyay; Pablo Tamayo; Wan Seok Yang; Matthew G Rees; Sixun Chen; Zarko V Boskovic; Sarah Javaid; Cherrie Huang; Xiaoyun Wu; Yuen-Yi Tseng; Elisabeth M Roider; Dong Gao; James M Cleary; Brian M Wolpin; Jill P Mesirov; Daniel A Haber; Jeffrey A Engelman; Jesse S Boehm; Joanne D Kotz; Cindy S Hon; Yu Chen; William C Hahn; Mitchell P Levesque; John G Doench; Michael E Berens; Alykhan F Shamji; Paul A Clemons; Brent R Stockwell; Stuart L Schreiber
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

10.  Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer.

Authors:  Lu Zhang; Di Jing; Lei Wang; Yuan Sun; Jian Jian Li; Brianna Hill; Fan Yang; Yuanpei Li; Kit S Lam
Journal:  Nano Lett       Date:  2018-10-26       Impact factor: 11.189
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.